MediGene finally gets RA treatment RhuDax into Phase I
This article was originally published in Scrip
Executive Summary
The UK medicines agency, the MHRA, has approved a Phase I trial for RhuDex, MediGene's potential rheumatoid arthritis treatment. The approval comes some three years after trials were suspended in the wake of safety concerns.